Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist”In the company’s words, NCT05427253 on ClinicalTrials.gov
- Tested for
- Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Main trialPhase 1
- “This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in healthy females of non-childbearing potential and healthy males. The trial will be conducted in 2 parts: Part A, single ascending dose (SAD) including a food interaction cohort: safety, tolerability, and PK in healthy males and healthy females of non-childbearing potential receiving single ascending doses of C106. Part B, multiple ascending dose (MAD): safety,…”In the company’s words, NCT05427253 on ClinicalTrials.gov
Other drugs for Tolerance
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- Efimosfermin AlfaGSK · Phase 3
- PegozaferminHoffmann-La Roche · 89bio, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- SemaglutideNovo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 22 Jun 2023 | First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026